Clinical trial CLEAR
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)
| Cancers | |
|---|---|
| Organ | Kidney |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Eisai Limited |
| EudraCT Identifier | 2016-000916-14 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02811861 |
| Inclusion criteria | First line metastatic |
| Last update |